^
    1d
    A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 positive • HR positive
    1d
    Does trastuzumab-related cardiotoxicity influence long-term outcome in patients with HER-2 positive breast cancer? A prospective study. (PubMed, Arch Med Sci)
    In a multivariate regression analysis the cumulative dose of anthracycline (OR = 1.01, 95% CI: 1.00-1.01, p = 0.002) and LVEF at baseline (OR = 0.83, 95% CI: 0.70-0.99, p = 0.0344) were independent predictors of a cardiotoxic effect. Trastuzumab-related cardiotoxicity resulting in early treatment discontinuation negatively influences DFS, but does not seem to influence OS.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab)
    1d
    HER2-low status in breast cancer: clinicopathological factors and prognostic value. (PubMed, Arch Med Sci)
    HER2-low status was associated with worse OS in breast cancer patients with certain negative prognostic factors compared with HER2-zero status. Additionally, HER2-low1+ and HER2-low2+/ISH(-) subgroups predominantly exhibited HR+ status.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HR positive • HER-2 overexpression • ER negative • HER-2 overexpression + HR positive • HER-2 positive + HER-2 overexpression
    1d
    Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial. (PubMed, Eur J Cancer)
    Obesity was associated with lower ORR with letrozole alone, whereas this association was not observed in patients treated with taselisib.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • IL6 (Interleukin 6)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    letrozole • taselisib (GDC-0032)
    1d
    Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study. (PubMed, Eur J Cancer)
    MRI-guided shorter neoadjuvant chemotherapy duration is associated with less pronounced declines and better long-term preservation of HRQOL in patients with early HER2-positive breast cancer. These findings support MRI-guided treatment de-escalation as a strategy to reduce survivorship burden without compromising efficacy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    1d
    Surgical Resection of Metastatic Male Breast Cancer to the Brain: An Illustrative Case Report. (PubMed, Clin Case Rep)
    Postoperatively, he received adjuvant stereotactic radiosurgery (30-35 Gy in five fractions) to the resection cavity and was transitioned from tamoxifen to trastuzumab deruxtecan (T-DXd) for improved CNS-directed systemic therapy. Surveillance imaging at 6 months demonstrated no intracranial recurrence, and systemic restaging showed no extracranial disease progression. This case highlights the importance of prompt neuroimaging for new neurological symptoms in male breast cancer patients and supports a multimodal strategy, including surgical resection, focal radiation, and CNS-penetrant HER2-targeted therapy, for achieving durable intracranial control in select patients with isolated brain metastasis.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • PGR positive
    |
    tamoxifen • Enhertu (fam-trastuzumab deruxtecan-nxki)
    1d
    Factors associated with local breast cancer recurrence after mastectomy in the Netherlands: a retrospective nationwide cohort study. (PubMed, Breast)
    We identified several factors associated with LR rates after mastectomy. Despite the observational character of our study, these factors could be considered in future treatment decision-making.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive
    1d
    Relationship between overall survival and progression-free survival with 18 F-FDG PET/CT metabolic parameters in metastatic breast cancer patients treated with CDK 4/6 inhibitors. (PubMed, Ir J Med Sci)
    Baseline 18 F-FDG PET/CT may provide prognostic insights in HR+/HER2- metastatic breast cancer. High MTV and TLG are associated with poorer OS in univariate analyses but not in multivariable analyses. ECOG score > 0 and age ≥ 60 years are independent predictors of PFS.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative
    1d
    Artificial Intelligence for Molecular Subtyping in Unresectable Gallbladder Cancer: A Proof-of-Concept Study for CT-based HER2 Status Prediction. (PubMed, J Clin Exp Hepatol)
    This study establishes a fully automated CT-based deep learning pipeline for HER2 status prediction in unresectable GBC. Validation in larger, multi-institutional cohorts is warranted.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 overexpression • HER-2 positive + HER-2 overexpression
    1d
    A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=71, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Avastin (bevacizumab) • capecitabine • oxaliplatin • TQB2930
    1d
    Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases (clinicaltrials.gov)
    P2, N=134, Recruiting, Brigham and Women's Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    1d
    SASHA: Single FrAction Interstitial BreaSt BracHytherApy (clinicaltrials.gov)
    P2, N=134, Not yet recruiting, Virginia Commonwealth University
    New P2 trial
    |
    PGR (Progesterone receptor)
    |
    HER-2 positive